Because PD-L1 suppresses T-cell function in tumor immune escape, our results suggested that the combination of chemotherapy regimens that target PD-L1 and IL-1 signaling is an effective strategy for osteosarcoma treatment. This evidence concerns the gene IL1A and neoplasm.